MARKET

PBYI

PBYI

Puma Biotechnology Inc
NASDAQ
8.77
+0.08
+0.92%
After Hours: 8.43 -0.34 -3.88% 19:34 08/11 EDT
OPEN
8.77
PREV CLOSE
8.69
HIGH
8.91
LOW
8.48
VOLUME
314.60K
TURNOVER
--
52 WEEK HIGH
9.40
52 WEEK LOW
3.710
MARKET CAP
452.71M
P/E (TTM)
18.38
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PBYI last week (0803-0807)?
Weekly Report · 1d ago
Puma Biotechnology (PBYI) Stock Jumps On Profit Strength As Earnings Outlook Fades
Simply Wall St · 4d ago
Puma Biotechnology Is Maintained at Hold by TD Cowen
Dow Jones · 4d ago
TD Cowen Maintains Hold on Puma Biotechnology, Raises Price Target to $6
Benzinga · 4d ago
Puma Biotechnology price target raised to $6 from $5 at TD Cowen
TipRanks · 4d ago
Analysts Offer Insights on Healthcare Companies: Neuren Pharmaceuticals Limited (OtherNURPF) and Puma Biotechnology (PBYI)
TipRanks · 5d ago
Puma Biotechnology sees Q3 revenue $56M-$59M
TipRanks · 5d ago
Puma Biotechnology raises FY26 revenue to $224M-$231M from $222M-$229M
TipRanks · 5d ago
More
About PBYI
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The Company is focused on the global development and commercialization of alisertib. Alisertib is a selective, small-molecule inhibitor of Aurora Kinase A that is designed to disrupt mitosis, leading to apoptosis of rapidly proliferating tumor cells.

Webull offers Puma Biotechnology Inc stock information, including NASDAQ: PBYI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PBYI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PBYI stock methods without spending real money on the virtual paper trading platform.